Artemether
Coartem (artemether) is a small molecule pharmaceutical. Artemether was first approved as Coartem on 2009-04-07. It is used to treat falciparum malaria and malaria in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Combinations
Coartem
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| coartem | New Drug Application | 2024-07-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| malaria | EFO_0001068 | D008288 | B54 |
| falciparum malaria | EFO_0007444 | D016778 | B50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
236 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 20 | 25 | 54 | 81 | 51 | 219 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 5 | 18 | 27 | 37 | 19 | 97 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 1 | — | 2 | 6 | 4 | 13 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | 1 | 6 | — | 9 |
| Infections | D007239 | EFO_0000544 | — | 2 | — | — | 2 | 2 | 6 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | 3 | 2 | 5 |
| Hiv | D006678 | — | — | 2 | — | — | 1 | — | 3 |
| Communicable diseases | D003141 | — | — | 1 | — | — | 1 | 1 | 3 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | 1 | — | 1 | — | 2 |
| Coinfection | D060085 | — | — | — | 1 | — | 1 | — | 2 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fever | D005334 | HP_0001945 | R50.9 | — | — | 1 | — | 2 | 3 |
| Body weight | D001835 | EFO_0004338 | — | — | 1 | 2 | — | — | 2 |
| Covid-19 | D000086382 | — | — | — | — | 1 | — | — | 1 |
| Disease susceptibility | D004198 | — | — | — | — | 1 | — | — | 1 |
| Asymptomatic diseases | D058070 | — | — | — | 1 | 1 | — | — | 1 |
| Blister | D001768 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | 2 | — | — | — | 4 |
| Combination drug therapy | D004359 | — | — | 2 | 1 | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | 1 | — | — | — | 2 |
| Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Ebola hemorrhagic fever | D019142 | EFO_0007243 | A98.4 | — | 1 | — | — | — | 1 |
| Virus diseases | D014777 | — | B34 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 1 | — | — | — | 4 | 5 |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | 2 | — | — | — | — | 2 |
| Parasitemia | D018512 | — | — | 2 | — | — | — | — | 2 |
| Protozoan infections | D011528 | — | B50-B64 | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 3 | 3 |
| Drug resistance | D004351 | — | Z16.30 | — | — | — | — | 1 | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 1 | 1 |
| Severe acute malnutrition | D000067011 | — | — | — | — | — | — | 1 | 1 |
| Hyperthermia | D000084462 | — | — | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 1 | 1 |
| Chemoprevention | D018890 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Artemether |
| INN | artemether |
| Description | Artemether is an artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria. It has a role as an antimalarial. It is a sesquiterpenoid, a cyclic acetal, an organic peroxide, an artemisinin derivative and a semisynthetic derivative. |
| Classification | Small molecule |
| Drug class | antimalarials (artemisin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3 |
Identifiers
| PDB | — |
| CAS-ID | 71963-77-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL566534 |
| ChEBI ID | 195280 |
| PubChem CID | 68911 |
| DrugBank | DB06697 |
| UNII ID | C7D6T3H22J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,757 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
321 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use